The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of a phase II study of cabozantinib in patients with MET-altered lung cancers.
 
Guilherme Harada
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Johnson & Johnson/Janssen; Lilly; Merck Sharp Dohme; Novartis; Takeda
 
Fernando Santini
No Relationships to Disclose
 
Rebecca Repetti
Employment - Memorial Sloan-Kettering Cancer Center
Honoraria - Physicans' Education Resource
Travel, Accommodations, Expenses - Memorial Sloan-Kettering Cancer Center
 
Jason Chang
No Relationships to Disclose
 
Soo-Ryum Yang
Honoraria - AstraZeneca; Medical Learning Institute; Medscape; OncLive/MJH Life Sciences; Prime Education; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; InVitae; Merus; Sanofi
(OPTIONAL) Uncompensated Relationships - Boehringer Ingelheim; Loxo/Lilly
 
Yun-Te Lin
No Relationships to Disclose
 
Khadeja Moses
No Relationships to Disclose
 
Christina Falcon
No Relationships to Disclose
 
Clare Wilhelm
Employment - Memorial Sloan-Kettering Cancer Center
 
Michelle Goldstein
No Relationships to Disclose
 
Alex Makhnin
No Relationships to Disclose
 
Michelle Ginsberg
No Relationships to Disclose
 
Andrew Plodkowski
No Relationships to Disclose
 
Mark Kris
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Astra Zeneca; Merck; Pfizer; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Genentech
 
Alexander Drilon
Stock and Other Ownership Interests - mBrace; Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EcoR1 Capital; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Osimertinib Selpercatinib; Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva